Susanne S. Hoeppner is an Assistant Professor of Psychiatry at Harvard Medical School (HMS) and is a member of the Massachusetts General Hospital (MGH) Biostatistics Center. She provides statistical guidance and expertise for various groups at MGH including the Center for OCD and Related Disorders (CORD), the Medical Practice Evaluation Center (MPEC), and the Recovery Research Institute (RRI). Her collaborative research effort has included applications in psychology, psychiatry, smoking cessation, and HIV/AIDS. She has served as the principal statistician on pivotal trials approved by the FDA and has designed and analyzed Phase I-III studies in addiction, psychiatry, and psychology. She also has ample experience setting up, updating, and overseeing the use of electronic data capture forms as implemented via REDCap, having designed and managed such databases for several single- and multi-site clinical trials at MGH. Dr. Hoeppner’s clinical interests are in dynamic health behavior modeling and positive psychology.
Dr. Hoeppner earned a PhD in Oceanography and Coastal Sciences and her Master of Applied Statistics from Louisiana State University. She also holds a MS in Biological Science from Southeastern Louisiana University.
Joseph J. Locascio, Ph.D. has had a research appointment as a Senior Biostatistician for the Alzheimer’s Disease Research Center and Memory/Movement Disorders Units, Department of Neurology at Massachusetts General Hospital (MGH), Boston, since 1992. He is an Assistant Professor of Neurology at Harvard Medical School as well as a Collaborating Statistician in the Neurology Dept. at Brigham and Women’s Hospital. He is a Consulting Statistician for the Harvard Catalyst Bio-Statistical Consulting Group of Harvard Medical School, and a member of the Statistical Advisory Boards for the journals PLOS One (Public Library of Science) and Lancet-Neurology.
Previously, Dr. Locascio had a dual appointment as research statistician in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology (MIT) from 1992 to 2009 where he also taught formal data analysis courses for four years. He has also taught statistics at Northwestern University (1982) and worked as a statistician in psychiatric research at the University of Chicago (1983-1985) and Bellevue Hospital/New York University Medical Center (1989-1991), and was Research Coordinator for the Mental Health Division of the Chicago Dept. of Health (1976-1979). He has over 100 publications in medical and scientific journals, magazines, and books.
Steven Skates is an Associate Professor of Medicine at Harvard Medical School and Associate Biostatistician at Massachusetts General Hospital.
His research interests focus on early detection of cancer, and include biomarker discovery and validation, development of early detection algorithms, and design, conduct, and analysis of early detection trials.
Tanayott Thaweethai (he/him) is Associate Director, Biostatistics Research and Engagement for MGH Biostatistics and an Instructor in Medicine at Harvard Medical School. He develops methods for handling missing data when conducting large observational studies using electronic health records. His research collaboration areas at Mass General include diabetes in pregnancy, clinical effectiveness of type 2 diabetes treatment, and several studies related to COVID-19. He is also lead biostatistician at the Data Resource Core for RECOVER, an NIH research initiative that seeks to understand post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID.
Dr. Thaweethai received his B.S. in Applied Mathematics – Biology from Brown University and Ph.D. in Biostatistics from Harvard University.
Mark Vangel is an Assistant Professor of Radiology at Harvard Medical School and a Biostatistician at MGH Biostatistics and the Martinos Center for Biomedical Imaging at MGH. He is also affiliated with the Ferenc Jolesz National Center for Image Guided Therapy at Brigham and Women’s Hospital and the Clinical Research Center at MIT.
His research interests include heteroscadasticity in meta-analysis and mixed-model regression, measurement uncertainty, statistical applications in functional MRI and diagnostic imaging, and Bayesian applications.
Dr. Vangel earned a PhD in Statistics from Harvard University, and SM and SB degrees in Mathematics from MIT.
Beow Yeap has collaborated closely with investigators in radiation oncology, radiation physics, medical oncology, molecular pathology, and thoracic surgery at the MGH Cancer Center and Dana-Farber/Harvard Cancer Center since joining MGH Biostatistics in 1999. She has developed extensive experience and expertise in design and analysis of clinical trials and correlative studies for adult and pediatric tumors, with primary focus on proton radiation therapy and molecularly targeted therapies.
Her contributions to translational research encompass preclinical models as well as human studies, including the identification and validation of biomarkers for prognosis and prediction of therapeutic benefit. She has played a leadership role in multi-disciplinary, multi-institutional research efforts as Director of the Biostatistics Core for the Program Project in proton therapy research and DF/HCC SPORE in Lung Cancer.
In between her degree studies for an A.M. in Statistics from the Harvard Graduate School of Arts & Sciences and an Sc.D. in Biostatistics from the Harvard School of Public Health, she gained valuable experience in cancer clinical trials at the Dana-Farber Cancer Institute.
Brian Healy is an Assistant Professor of Neurology at Harvard Medical School (HMS) and an Assistant Professor in Biostatistics at the Harvard T.H. Chan School of Public Health. He is the primary biostatistician for the Partners MS Center at Brigham and Women’s Hospital, and he is a member of the Massachusetts General Hospital (MGH) Biostatistics Center. Dr. Healy has been the instructor for many courses related to biostatistics at HMS and Harvard T.H. Chan School of Public Health. Dr. Healy’s research focuses on modeling the disease course in patients with multiple sclerosis.
He obtained his PhD in Biostatistics from the Harvard T.H. Chan School of Public Health in 2007.
Eric Macklin is an Investigator in Investigation at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.
He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson’s Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.
Dr. Macklin earned a PhD from Duke University and also holds an MS from Stanford University and an MSc from the Harvard T.H. Chan School of Public Health.